Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B.

Cheung LH, Zhao Y, Alvarez-Cienfuegos A, Mohamedali KA, Cao YJ, Hittelman WN, Rosenblum MG.

J Exp Clin Cancer Res. 2019 Jul 30;38(1):332. doi: 10.1186/s13046-019-1333-6.

2.

Light-enhanced VEGF121/rGel: A tumor targeted modality with vascular and immune-mediated efficacy.

Weyergang A, Fremstedal AS, Skarpen E, Peng Q, Mohamedali KA, Eng MS, Cheung LH, Rosenblum MG, Waltenberger J, Berg K.

J Control Release. 2018 Oct 28;288:161-172. doi: 10.1016/j.jconrel.2018.09.005. Epub 2018 Sep 11.

PMID:
30217739
3.

Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2.

Redis RS, Vela LE, Lu W, Ferreira de Oliveira J, Ivan C, Rodriguez-Aguayo C, Adamoski D, Pasculli B, Taguchi A, Chen Y, Fernandez AF, Valledor L, Van Roosbroeck K, Chang S, Shah M, Kinnebrew G, Han L, Atlasi Y, Cheung LH, Huang GY, Monroig P, Ramirez MS, Catela Ivkovic T, Van L, Ling H, Gafà R, Kapitanovic S, Lanza G, Bankson JA, Huang P, Lai SY, Bast RC, Rosenblum MG, Radovich M, Ivan M, Bartholomeusz G, Liang H, Fraga MF, Widger WR, Hanash S, Berindan-Neagoe I, Lopez-Berestein G, Ambrosio ALB, Gomes Dias SM, Calin GA.

Mol Cell. 2016 Feb 18;61(4):640. doi: 10.1016/j.molcel.2016.02.006. Epub 2016 Feb 18. No abstract available.

4.

Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2.

Redis RS, Vela LE, Lu W, Ferreira de Oliveira J, Ivan C, Rodriguez-Aguayo C, Adamoski D, Pasculli B, Taguchi A, Chen Y, Fernandez AF, Valledor L, Van Roosbroeck K, Chang S, Shah M, Kinnebrew G, Han L, Atlasi Y, Cheung LH, Huang GY, Monroig P, Ramirez MS, Catela Ivkovic T, Van L, Ling H, Gafà R, Kapitanovic S, Lanza G, Bankson JA, Huang P, Lai SY, Bast RC, Rosenblum MG, Radovich M, Ivan M, Bartholomeusz G, Liang H, Fraga MF, Widger WR, Hanash S, Berindan-Neagoe I, Lopez-Berestein G, Ambrosio ALB, Gomes Dias SM, Calin GA.

Mol Cell. 2016 Feb 18;61(4):520-534. doi: 10.1016/j.molcel.2016.01.015. Epub 2016 Feb 4. Erratum in: Mol Cell. 2016 Feb 18;61(4):640.

5.

Design of an EGFR-targeting toxin for photochemical delivery: in vitro and in vivo selectivity and efficacy.

Berstad MB, Cheung LH, Berg K, Peng Q, Fremstedal AS, Patzke S, Rosenblum MG, Weyergang A.

Oncogene. 2015 Oct 29;34(44):5582-92. doi: 10.1038/onc.2015.15. Epub 2015 Feb 16.

PMID:
25684137
6.

Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC.

Zhou H, Mohamedali KA, Gonzalez-Angulo AM, Cao Y, Migliorini M, Cheung LH, LoBello J, Lei X, Qi Y, Hittelman WN, Winkles JA, Tran NL, Rosenblum MG.

Mol Cancer Ther. 2014 Nov;13(11):2688-705. doi: 10.1158/1535-7163.MCT-14-0346. Epub 2014 Sep 19.

7.

Photochemical internalization augments tumor vascular cytotoxicity and specificity of VEGF(121)/rGel fusion toxin.

Weyergang A, Cheung LH, Rosenblum MG, Mohamedali KA, Peng Q, Waltenberger J, Berg K.

J Control Release. 2014 Apr 28;180:1-9. doi: 10.1016/j.jconrel.2014.02.003. Epub 2014 Feb 13.

PMID:
24531010
8.

The functionalized human serine protease granzyme B/VEGF₁₂₁ targets tumor vasculature and ablates tumor growth.

Mohamedali KA, Cao Y, Cheung LH, Hittelman WN, Rosenblum MG.

Mol Cancer Ther. 2013 Oct;12(10):2055-66. doi: 10.1158/1535-7163.MCT-13-0165. Epub 2013 Jul 15.

9.

Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors.

Zhou H, Hittelman WN, Yagita H, Cheung LH, Martin SS, Winkles JA, Rosenblum MG.

Cancer Res. 2013 Jul 15;73(14):4439-50. doi: 10.1158/0008-5472.CAN-13-0187. Epub 2013 May 30.

10.

Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neu.

Cao Y, Mohamedali KA, Marks JW, Cheung LH, Hittelman WN, Rosenblum MG.

Mol Cancer Ther. 2013 Jun;12(6):979-91. doi: 10.1158/1535-7163.MCT-13-0002. Epub 2013 Mar 14.

11.

Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.

Cao Y, Marks JW, Liu Z, Cheung LH, Hittelman WN, Rosenblum MG.

Oncogene. 2014 Jan 23;33(4):429-39. doi: 10.1038/onc.2012.612. Epub 2013 Feb 4.

12.

The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma.

Lyu MA, Pham LV, Sung B, Tamayo AT, Ahn KS, Hittelman WN, Cheung LH, Marks JW, Cho MJ, Ford RJ, Aggarwal BB, Rosenblum MG.

Biochem Pharmacol. 2012 Aug 15;84(4):451-8. doi: 10.1016/j.bcp.2012.05.019. Epub 2012 Jun 9.

PMID:
22687624
13.

Bax345/BLyS: a novel, completely human fusion protein targeting malignant B cells and delivering a unique mitochondrial toxin.

Lyu MA, Cheung LH, Hittelman WN, Liu Y, Marks JW, Cho MJ, Rosenblum MG.

Cancer Lett. 2012 Sep 28;322(2):159-68. doi: 10.1016/j.canlet.2012.02.029. Epub 2012 Mar 1.

PMID:
22388102
14.

Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.

Cao Y, Marks JD, Huang Q, Rudnick SI, Xiong C, Hittelman WN, Wen X, Marks JW, Cheung LH, Boland K, Li C, Adams GP, Rosenblum MG.

Mol Cancer Ther. 2012 Jan;11(1):143-53. doi: 10.1158/1535-7163.MCT-11-0519. Epub 2011 Nov 16.

15.

Cytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2.

Mohamedali KA, Ran S, Gomez-Manzano C, Ramdas L, Xu J, Kim S, Cheung LH, Hittelman WN, Zhang W, Waltenberger J, Thorpe PE, Rosenblum MG.

BMC Cancer. 2011 Aug 17;11:358. doi: 10.1186/1471-2407-11-358.

16.

Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells.

Zhou H, Marks JW, Hittelman WN, Yagita H, Cheung LH, Rosenblum MG, Winkles JA.

Mol Cancer Ther. 2011 Jul;10(7):1276-88. doi: 10.1158/1535-7163.MCT-11-0161. Epub 2011 May 17.

17.

Targeting granzyme B to tumor cells using a yoked human chorionic gonadotropin.

Kanatani I, Lin X, Yuan X, Manorek G, Shang X, Cheung LH, Rosenblum MG, Howell SB.

Cancer Chemother Pharmacol. 2011 Oct;68(4):979-90. doi: 10.1007/s00280-011-1573-4. Epub 2011 Feb 16.

18.

Characterization and mechanistic studies of a novel melanoma-targeting construct containing IκBa for specific inhibition of nuclear factor-κB activity.

Zhou H, Liu Y, Cheung LH, Kim S, Zhang W, Mohamedali KA, Anand P, Hittelman WN, Aggarwal BB, Rosenblum MG.

Neoplasia. 2010 Oct;12(10):766-77.

19.

The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphoma.

Lyu MA, Sung B, Cheung LH, Marks JW, Aggarwal BB, Aguiar RC, Rosenblum MG.

Biochem Pharmacol. 2010 Nov 1;80(9):1335-42. doi: 10.1016/j.bcp.2010.07.017. Epub 2010 Jul 21.

PMID:
20654581
20.

The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo.

Lyu MA, Rai D, Ahn KS, Sung B, Cheung LH, Marks JW, Aggarwal BB, Aguiar RC, Gandhi V, Rosenblum MG.

Neoplasia. 2010 May;12(5):366-75.

21.

Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.

Cao Y, Marks JD, Marks JW, Cheung LH, Kim S, Rosenblum MG.

Cancer Res. 2009 Dec 1;69(23):8987-95. doi: 10.1158/0008-5472.CAN-09-2693. Epub 2009 Nov 24.

22.

Multi-modality therapeutics with potent anti-tumor effects: photochemical internalization enhances delivery of the fusion toxin scFvMEL/rGel.

Selbo PK, Rosenblum MG, Cheung LH, Zhang W, Berg K.

PLoS One. 2009 Aug 19;4(8):e6691. doi: 10.1371/journal.pone.0006691.

23.

Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors.

Yuan X, Lin X, Manorek G, Kanatani I, Cheung LH, Rosenblum MG, Howell SB.

Mol Cancer Ther. 2009 Jul;8(7):1906-15. doi: 10.1158/1535-7163.MCT-09-0106. Epub 2009 Jun 30.

24.

Evaluation of a rotary instrumentation method for C-shaped canals with micro-computed tomography.

Cheung LH, Cheung GS.

J Endod. 2008 Oct;34(10):1233-8. doi: 10.1016/j.joen.2008.07.015. Epub 2008 Aug 23.

PMID:
18793928
25.

Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis.

Martínez-Torrecuadrada JL, Cheung LH, López-Serra P, Barderas R, Cañamero M, Ferreiro S, Rosenblum MG, Casal JI.

Mol Cancer Ther. 2008 Apr;7(4):862-73. doi: 10.1158/1535-7163.MCT-07-0394.

26.

Improved expression of a soluble single chain antibody fusion protein containing tumor necrosis factor in Escherichia coli.

Kim S, Cheung LH, Zhang W, Rosenblum MG.

Appl Microbiol Biotechnol. 2007 Nov;77(1):99-106. Epub 2007 Aug 17.

PMID:
17703297
27.

Root morphology--a study of the mandibular second molar of ethnic Chinese.

Cheung LH, D L, Cheung GS.

Ann R Australas Coll Dent Surg. 2006 Sep;18:47-50.

PMID:
17668593
28.

The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA.

Lyu MA, Cheung LH, Hittelman WN, Marks JW, Aguiar RC, Rosenblum MG.

Mol Cancer Ther. 2007 Feb;6(2):460-70. Epub 2007 Jan 31.

29.

Overexpression of biologically active VEGF121 fusion proteins in Escherichia coli.

Kim S, Mohamedali KA, Cheung LH, Rosenblum MG.

J Biotechnol. 2007 Feb 20;128(3):638-47. Epub 2006 Dec 12.

PMID:
17218033
30.

The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts.

Liu Y, Zhang W, Cheung LH, Niu T, Wu Q, Li C, Van Pelt CS, Rosenblum MG.

Neoplasia. 2006 May;8(5):384-93.

31.

Targeted apoptosis activation with GrB/scFvMEL modulates melanoma growth, metastatic spread, chemosensitivity, and radiosensitivity.

Liu Y, Zhang W, Niu T, Cheung LH, Munshi A, Meyn RE Jr, Rosenblum MG.

Neoplasia. 2006 Feb;8(2):125-35.

32.
33.
35.
36.

A controlled trial of psycho-educational interventions in preparing Chinese women for elective hysterectomy.

Cheung LH, Callaghan P, Chang AM.

Int J Nurs Stud. 2003 Feb;40(2):207-16.

PMID:
12559144
37.

Different trends in modulation of NMDAR1 and NMDAR2B gene expression in cultured cortical and hippocampal neurons after lead exposure.

Lau WK, Yeung CW, Lui PW, Cheung LH, Poon NT, Yung KK.

Brain Res. 2002 Apr 5;932(1-2):10-24.

PMID:
11911857
38.

Erratum

Rosenblum MG, Horn SA, Cheung LH.

Int J Cancer. 2000 Dec 15;88(6):1009. No abstract available.

39.

A novel recombinant fusion toxin targeting HER-2/NEU-over-expressing cells and containing human tumor necrosis factor.

Rosenblum MG, Horn SA, Cheung LH.

Int J Cancer. 2000 Oct 15;88(2):267-73. Erratum in: Int J Cancer. 2000 Dec 15;88(6):1009.

40.

Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin.

Rosenblum MG, Marks JW, Cheung LH.

Cancer Chemother Pharmacol. 1999;44(4):343-8.

PMID:
10447583
41.

Isolation of flagella and their membranes from sea urchin spermatozoa.

Cheung LH.

Methods Cell Biol. 1995;47:43-6. No abstract available.

PMID:
7476524
42.

Supplemental Content

Loading ...
Support Center